xpertsystems/hconc013-sample

HC-ONC-013是一个合成数据集，专注于免疫治疗（检查点抑制剂）响应队列，来自XpertSystems.ai合成数据工厂的肿瘤学垂直领域（SKU 13）。该数据集包含500名患者的单表队列，覆盖8种癌症类型（如非小细胞肺癌、黑色素瘤、肾细胞癌等）和8种检查点抑制剂药物（包括抗PD-1、抗PD-L1、抗CTLA-4及联合疗法），具有全面的预测性生物标志物面板（如PD-L1表达、肿瘤突变负荷、微卫星不稳定性等）、11个器官系统的免疫相关不良事件（irAE）配置文件（使用CTCAE v5.0分级）、RECIST 1.1响应评估（包括假性进展和超进展标志）、ctDNA动态变化以及生存终点（如无进展生存期、总生存期）。数据集设计用于免疫治疗结果分析、irAE风险建模、预测性生物标志物发现、生物标志物分层响应分析和检查点抑制剂序列研究，同时保持100%合成性，无真实患者数据或隐私风险。数据以CSV格式提供，包含128列，分为9个模块（如人口统计学、肿瘤生物标志物、治疗分配、irAE模拟等），并经过校准以匹配行业标准试验数据。

HC-ONC-013 is a synthetic dataset focusing on an immunotherapy (checkpoint inhibitor) response cohort, derived from the XpertSystems.ai Synthetic Data Factorys oncology vertical (SKU 13). The dataset includes a single-table cohort of 500 patients, spanning 8 cancer types (e.g., NSCLC, melanoma, RCC) and 8 checkpoint inhibitor agents (including anti-PD-1, anti-PD-L1, anti-CTLA-4, and combination therapies), with a comprehensive predictive biomarker panel (e.g., PD-L1 expression, tumor mutational burden, microsatellite instability), 11 organ-system immune-related adverse event (irAE) profiles (graded using CTCAE v5.0), RECIST 1.1 response assessment (including pseudoprogression and hyperprogression flags), ctDNA dynamics, and survival endpoints (such as progression-free survival and overall survival). It is designed for immunotherapy outcomes analytics, irAE risk modeling, predictive biomarker discovery, biomarker-stratified response analysis, and CPI sequencing research, while remaining 100% synthetic with no real patient data or privacy risks. The data is provided in CSV format with 128 columns across 9 modules (e.g., demographics, tumor biomarkers, treatment assignment, irAE simulation) and is calibrated against industry-grade trial data.